DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

Key points

• Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it.1
• Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled.1
• We evaluated nine agents in 540 episodes across 20 cardiovascular worlds and three experimental budgets.1
• By making each world's causal structure known to the evaluator but hidden from the agent, DrugTargetWorld turns end-to-end drug target discovery into a scalable training and evaluation problem with verifiable reward.1

Sources (1)

• [1]DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists
  arXiv (AI, ML, NLP, CV, robotics, multi-agent) · Oct 7, 06:59 AM

  We introduce DrugTargetWorld, a framework that procedurally generates simulated biobanks, or "worlds," with known but concealed causal structure.

  Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it.

Extractive summary: sentences quoted from the sources.